Torin-1 - mTOR 抑制剂 - 生命科学试剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETorin 1Cat. No.: HY-13003CAS No.: 1222998-36-8分式: CHFNO分量: 607.62作靶点: mTOR; Autophagy作通路: PI3K/Akt/mTOR; Autophagy储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 6.6 mg/mL (10.86 mM; Need u

2、ltrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.6458 mL 8.2288 mL 16.4577 mL5 mM 0.3292 mL 1.6458 mL 3.2915 mL10 mM 0.1646 mL 0.8229 mL 1.6458 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 Torin 1 is dissolved in 100% N-methyl-2-pyrrolidone and subsequently diluted wi

3、th PEG400 and water at theratio of 1:2:23. Torin 1 is dissolved in NMP/PEG 400 (1:4)4.BIOLOGICAL ACTIVITY物活性 Torin 1种有效的 mTOR 抑制剂，IC50 为 3 nM。Torin 1 抑制 mTORC1/2 复合物，IC50 值在 2 和 10 nM之间。IC50 & Target mTORC1 mTORC2 mTOR DNA-PK1/3 Master of Small Molecules 您边的抑制剂师www.MedChemE2-10 nM (IC50) 2-10 nM (IC

4、50) 3 nM (IC50) 1 M (IC50)PI3K- ATM hVps34 Autophagy1.8 M (IC50) 0.6 M (IC50) 3 M (IC50)体外研究 Torin1 (250 nM) completely inhibits proliferation and causes a G1/S cell cycle arrest, and decreases cell sizeto a greater degree than 50 nM rapamycin in wild-type MEFs 1. Torin1 has more than 800-fold selec

5、tivitybetween mTOR and PI3Kis, and is very selective relative to other PIKK family kinases with the exception ofDNA-PK 2.体内研究 Torin1 (20 mg/kg, i.p.) is efficacious in a U87MG xenograft model, and demonstrates goodpharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tis

6、sues 2.PROTOCOLKinase Assay 1 To produce soluble mTORC1, HEK-293T cell lines are generated that stably express N-terminally FLAG-tagged Raptor using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, HeLa cellsare generated that stably express N-terminally FLAG-tagged Protor-1. Bo

7、th complexes are purified by lysingcells in 50 mM HEPES, pH 7.4, 10 mM sodium pyrophosphate, 10 mM sodium -glycerophosphate, 100 mMNaCl, 2 mM EDTA, 0.3% CHAPS. Cells are lysed at 4C for 30 min, and the insoluble fraction is removed bymicrocentrifugation at 13,000 rpm for 10 min. Supernatants are inc

8、ubated with FLAG-M2 monoclonalantibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing afinal concentration of 0.5 mol/L NaCl. Purified mTORC1 is eluted with 100 g/mL 3 FLAG peptide in 50 mMHEPES, pH 7.4, 100 mM NaCl. Eluate can be aliquoted and st

9、ored at -80C. Kinase assays are performedfor 20 min at 30C in a final volume of 20 L consisting of the kinase buffer (25 mM HEPES, pH 7.4, 50 mMKCl, 10 mM MgCl2, 500 M ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stoppedby the addition of 80 L of sample buffer and boiled for

10、 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treatedwith the ap

11、propriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubatedfor 60 min at room temperature; 50 L of CellTiter-Glo reagent is added to each well, and plates are mixedon an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer.MCE has no

12、t independently confirmed the accuracy of these methods. They are for reference only.Animal For pharmacodynamic experiments, torin 1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-Administration 2 pyrrolidone and then diluted 1:4 with sterile 50% PEG400 prior to injection. Six-week old mal

13、e C57BL/6 miceare fasted overnight prior to drug treatment. The mice are treated with vehicle (for 10 hr) or 26 (20 mg/kg for2, 6 or 10 hr) by IP injection, and then refed 1 h prior to sacrifice (CO2 asphyxiation). Tissues are collectedand frozen on dry ice. The frozen tissue is thawed on ice and ly

14、sed by sonication in tissue lysis buffer (50mM HEPES, pH 7.4, 40 mM NaCl, 2 mM EDTA, 1.5 mM sodium orthovanadate, 50 mM sodium fluoride, 10mM sodium pyrophosphate, 10 mM sodium -glycerophosphate, 0.1% SDS, 1.0% sodium deoxycholate and2/3 Master of Small Molecules 您边的抑制剂师www.MedChemE1.0% Triton, supp

15、lemented with protease inhibitor cocktail tablets). The concentration of clear lysate ismeasured using the Bradford assay and samples are subsequently normalized by protein content andanalyzed by SDSand immunoblotting.MCE has not independently confirmed the accuracy of these methods. They are for re

16、ference only.户使本产品发表的科研献 Cell Metab. 2018 Jan 9;27(1):118-135.e8. Cell Syst. 2018 Dec. Haematologica. 2017 Apr;102(4):755-764. Cell Death Dis. 2018 Oct 9;9(10):1032. Cell Death Dis. 2018 May 22;9(6):604.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Thoreen CC, et al, An ATP-c

17、ompetitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. JBiol Chem, 2009, 284(12), 8023-8032.2. Liu Q, et al. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzoh1,6naphthyridin-2(1H)-oneas a highly potent, selec

18、tive mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem. 2010 Oct14;53(19):7146-55.3. Bi C, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors inaggressive B-cell lymphomas. Haematologica. 2017 Apr;102(4):755-764.4. Brandt M, et al. mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects